BioLineRx Ltd. — Capital/Financing Update 2019

Feb 7, 2019

_________ false

������� �� ��� ��"�	2 380
BIOLINE RX LTD
Corporation no: 513398750	9253
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	07/02/2019
	www.isa.gov.il			www.tase.co.il				Reference:	2019-02-013341	Time of broadcast: 19:05 19:04:28

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

Please note that in the case of delayed publication of report, no changes will be allowed after the form is submitted.

	Delay the publication of a report	_________	_________

1. The delay of the report can be done up to 72 hours maximum from the date of filling out the form.2. Attention that in accordance with the provisions of the law, the reporting date must be simultaneous with the report in the foreign exchange.

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onBioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

6-K_closing_070219_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
2019-02-012771
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 31/12/2018
Address: HaMa'ayan 2 , Modi'in 7177871   , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: info@BioLineRx.com   Company site: www.biolinerx.com
Previous names of reporting entity:
Name of the Signatory: Kotler Norman Harold Position of Signatory in the reporting corporation: General Counsel & Company Secretary Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: normank@biolinerx.com 1
Israel